USAMRIID Marburg study advances towards dosing

• 22 non-human primates completed screening and preparation
• Study set to begin in Q4 CY2026 at USAMRIID
• Aims to optimize dosing for Galidesivir against Marburg virus

Island Pharmaceuticals Limited has announced that 22 non-human primates (NHPs) have successfully completed the screening and preparation phase for its planned 20-animal Galidesivir dose optimization study at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). The completion of these activities marks an important milestone in the company's development program for Galidesivir, an antiviral drug with potential efficacy against the Marburg virus. The study, to be conducted in USAMRIID's Biosafety Level 4 facilities, will evaluate the drug's efficacy against the Angola strain of Marburg virus, with dosing expected to commence during the current quarter. This study is part of a coordinated development program designed to inform the design of a pivotal study under the FDA Animal Rule pathway.